primary variable

(redirected from primary outcome variable)

primary variable

A term used in clinical trials for the outcome variable specified in the study protocol that is of greatest importance to the trial’s primary objective, and usually the one used in the sample size calculation.
References in periodicals archive ?
The primary outcome variable was mortality at 30 days from hospital admission.
The primary outcome variable was the delayed recall score from the Rey Auditory Verbal Learning Test (AVLT).
The CAPS-2 (symptom version) change from baseline to end point served as the primary outcome variable of the study.
The primary outcome variable was the change of the sum score of the U PDRS parts II and III between baseline and 3-month visits.
The primary outcome variable [POV] was a composite of changes from baseline in three co-primary, self-reported measures: Pain Visual Analog Scale [PVAS], captured with electronic diaries; Fibromyalgia Impact Questionnaire total score [FIQ]; and Patient Global Impression of Change [PGIC].
THE STUDY - Significant benefit in the primary outcome variable (POV) was seen with both doses of sodium oxybate compared with placebo [illustrated by 4.
For example, the placebo response rate for the primary outcome variable in this study exceeded 50 percent, higher than what we have seen in our previous trials involving several hundred patients.
On the primary outcome variable (time to discontinuations for all causes over a 48-hour period), oxymorphone IR 20 mg and 10 mg, given every four to six hours, were both superior to placebo (p<0.
It has been used as a primary outcome variable in studies that have formed the basis of regulatory dossiers for approved ED products.
No statistically significant difference in the primary outcome variable was observed in the MorphiDex(R) group compared to the morphine sulfate alone group.
The preliminary results of the primary outcome variable of this study show patients taking a controlled-release version of oxymorphone formulated with Penwest's TIMERx(R) delivery technology demonstrated a statistically significant reduction in pain intensity compared to placebo (p=0.
Our primary outcome variables of interest were HIV serostatus and condom use consistency.